Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies ; volume:100 ; number:11 ; day:31 ; month:8 ; year:2021 ; pages:2707-2716 ; date:11.2021
Annals of hematology ; 100, Heft 11 (31.8.2021), 2707-2716, 11.2021
- Creator
-
Sekhri, Rohit
Sadjadian, Parvis
Becker, Tatjana
Kolatzki, Vera
Huenerbein, Karlo
Meixner, Raphael
Marchi, Hannah
Wallmann, Rudolf
Fuchs, Christiane
Griesshammer, Martin
Wille, Kai
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-021-04647-0
- URN
-
urn:nbn:de:101:1-2021122620155188227375
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-15T07:27:26+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sekhri, Rohit
- Sadjadian, Parvis
- Becker, Tatjana
- Kolatzki, Vera
- Huenerbein, Karlo
- Meixner, Raphael
- Marchi, Hannah
- Wallmann, Rudolf
- Fuchs, Christiane
- Griesshammer, Martin
- Wille, Kai
- SpringerLink (Online service)
Other Objects (12)
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
A case of AORPA in an adult presenting as secondary polycythemia
Secondary polycythemia in chronic obstructive pulmonary disease: prevalence and risk factors
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
JAK2 Negative Polycythemia Vera
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
Breaking Stereotypes: Polycythemia Secondary to Shisha Smoking in a Middle-Age Swiss Woman
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
A case of AORPA in an adult presenting as secondary polycythemia
Secondary polycythemia in chronic obstructive pulmonary disease: prevalence and risk factors
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
JAK2 Negative Polycythemia Vera
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
Breaking Stereotypes: Polycythemia Secondary to Shisha Smoking in a Middle-Age Swiss Woman
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
A case of AORPA in an adult presenting as secondary polycythemia
Secondary polycythemia in chronic obstructive pulmonary disease: prevalence and risk factors
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
JAK2 Negative Polycythemia Vera
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera